Natera/NTRA

$94.47

-2.31%
-
1D1W1MYTD1YMAX

About Natera

Natera, Inc. is a diagnostics company, which is focused on the development and commercialization of molecular testing services, applying its technology in the fields of women’s health, oncology and organ health. Its cell-free deoxyribonucleic acid (cfDNA) technology combines its molecular assays, which reliably measure many informative regions across the genome from samples as small as a single cell. The Company's product offerings include Panorama Non-Invasive Prenatal Test (NIPT), Vistara, Horizon Carrier Screening, Spectrum Preimplantation Genetics, Anora Miscarriage Test, Empower, and Prospera. The Company also offers Constellation, a cloud-based software platform that enables laboratory customers to gain access through the cloud to the Company’s algorithms and bioinformatics in order to validate and launch tests based on the Company’s technology. Its NIPT screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother.

Ticker

NTRA

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Matthew Rabinowitz

Employees

3,282

Headquarters

Austin, United States

Natera Metrics

BasicAdvanced
$11.41B
Market cap
-
P/E ratio
-$3.80
EPS
1.38
Beta
-
Dividend rate
$11.41B
1.38351
$98.82
$36.90
1.46M
4.096
3.963
36.97
47.476
-30.66%
-59.11%
-39.2%
10.538
14.761
14.906
31.99%
31.77%
40.42%

What the Analysts think about Natera

Analyst Ratings

Majority rating from 17 analysts.
Buy

Price Targets

Average projection from 16 analysts.
4.93% upside
High $120.00
Low $37.00
$94.47
Current price
$99.13
Average price target

Natera Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-25.07% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$311.1M
15.95%
Net income
$-78M
-28.44%
Profit margin
-25.07%
-38.28%

Natera Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 12.03%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$1.23
-$0.97
-$0.95
-$0.64
-
Expected
-$1.15
-$1.09
-$0.96
-$0.73
-$0.71
Surprise
6.56%
-11.35%
-0.6%
-12.03%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Natera stock?

Natera (NTRA) has a market cap of $11.41B as of April 15, 2024.

What is the P/E ratio for Natera stock?

The price to earnings (P/E) ratio for Natera (NTRA) stock is 0 as of April 15, 2024.

Does Natera stock pay dividends?

No, Natera (NTRA) stock does not pay dividends to its shareholders as of April 15, 2024.

When is the next Natera dividend payment date?

Natera (NTRA) stock does not pay dividends to its shareholders.

What is the beta indicator for Natera?

Natera (NTRA) has a beta rating of 1.38. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the Natera stock price target?

The target price for Natera (NTRA) stock is $99.13, which is 4.93% above the current price of $94.47. This is an average based on projections from 16 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Natera stock

Buy or sell Natera stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing